Dr Reddy's Laboratories (DRREDDY) Weekly Analysis
Price & Volume
The stock price declined by 2.18% over the past week, ending at 1275.1. Trading volume dropped significantly by 62.07% compared to the previous week. The stock is currently trading near both its 50-day and 200-day moving averages. Price movement remained within a narrow range of 2.15% during this period.
Technicals
The stock price closed at 1275.1 this week, reflecting a 2.18% decline. The 20-week Moving Average (MA), which tracks the average price over 20 weeks, sits at 1275.43 with an upward slope. The 50-week MA, representing the 50-week average, is at 1264.88 with a downward slope. Momentum indicators show a decline, with the Relative Strength Index (RSI) at 44.95, indicating weaker momentum. The MACD histogram, which measures the gap between short-term and long-term price trends, is at -7.44, reflecting a bearish alignment. Volatility, measured by Bollinger Band width, increased to 7.81%.
Fundamentals
In the quarter ending March 2026, Dr Reddy's Laboratories reported a revenue of ₹7,546.0, a decrease of 11.5% year-over-year. Net profit also saw a significant decline of 86.1% year-over-year to ₹221.0. The operating margin for the quarter was 5.0%. The company currently trades at a Price-to-Earnings (PE) ratio of 33.1x and a Price-to-Book (PB) ratio of 3.4x. Dividend yield stands at 0.63%. The recent performance indicates a challenging period with notable drops in both top-line and bottom-line figures.
News
During the week of June 1, 2026, to June 5, 2026, Dr. Reddy's Laboratories experienced downward pressure on its stock price, recording declines for five consecutive sessions. Market sentiment remained mixed as investors evaluated the company's growth potential amidst a challenging environment and concerns regarding recent earnings per share trends. In corporate developments, management scheduled an investor meeting with Bank of America, which took place on June 5, 2026. While some analysts continued to include the stock in their top picks, the overall market performance reflected technical momentum shifts and cautious investor sentiment throughout the period.
Events
Dr. Reddy’s Laboratories has allotted 12,100 equity shares of Re. 1 each to eligible employees following the exercise of stock options under its existing ESOP schemes. This issuance increases the company's total paid-up share capital.
Dr. Reddy's Laboratories has announced a schedule of upcoming in-person group meetings with institutional investors organized by ICICI Securities and Macquarie on June 9 and June 10, 2026.
Dr. Reddy’s Laboratories has announced that its management will participate in an in-person group meeting organized by Bank of America in Hyderabad on June 5, 2026.
Dr. Reddy’s Laboratories has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the fiscal year ended March 31, 2026, providing shareholders with the company's consolidated financial statements prepared under IFRS.
Dr. Reddy's Laboratories has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, in accordance with SEBI listing regulations.
Dr. Reddy’s Laboratories reported Q4 FY26 revenues of ₹7,516 crore, with full-year revenues reaching ₹33,593 crore. The results reflect double-digit growth in the base business, though profitability was impacted by specific one-time items including shelf stock adjustments and impairment charges.
Dr. Reddy's Laboratories reported resilient FY26 performance with double-digit base business growth, despite one-time charges including a ₹453 crore shelf stock adjustment for lenalidomide. The Board recommended a dividend of ₹8 per equity share, reflecting the company's focus on operational efficiency and long-term growth.
Dr. Reddy’s Laboratories reported FY26 revenue of ₹33,593 crore, achieving 3% year-on-year growth despite product-specific headwinds in North America. The company maintained a net cash surplus of ₹3,271 crore while securing key regulatory approvals for generic semaglutide products.
Dr. Reddy's Laboratories has announced a schedule of upcoming in-person group meetings with institutional investors organized by ICICI Securities and Macquarie on June 9 and June 10, 2026.
Dr. Reddy’s Laboratories has announced that its management will participate in an in-person group meeting organized by Bank of America in Hyderabad on June 5, 2026.
Dr. Reddy’s Laboratories has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the fiscal year ended March 31, 2026, providing shareholders with the company's consolidated financial statements prepared under IFRS.
Dr. Reddy's Laboratories has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, in accordance with SEBI listing regulations.
Dr. Reddy’s Laboratories reported Q4 FY26 revenues of ₹7,516 crore, with full-year revenues reaching ₹33,593 crore. The results reflect double-digit growth in the base business, though profitability was impacted by specific one-time items including shelf stock adjustments and impairment charges.
Dr. Reddy's Laboratories reported resilient FY26 performance with double-digit base business growth, despite one-time charges including a ₹453 crore shelf stock adjustment for lenalidomide. The Board recommended a dividend of ₹8 per equity share, reflecting the company's focus on operational efficiency and long-term growth.
Dr. Reddy’s Laboratories reported FY26 revenue of ₹33,593 crore, achieving 3% year-on-year growth despite product-specific headwinds in North America. The company maintained a net cash surplus of ₹3,271 crore while securing key regulatory approvals for generic semaglutide products.
Weekly Snapshot
Highlights
- The stock declined by 2.18% this week, marking a five-session losing streak amid cooling momentum.
- Trading volume dropped significantly by 62.07% compared to the previous week, indicating reduced market participation.
- Technical indicators show a bearish alignment with the MACD histogram at -7.44 and the RSI at 44.95.
- Management engaged with institutional investors through meetings with Bank of America on June 5, 2026.
- The company filed its Annual Report on Form 20-F with the SEC for the fiscal year ended March 31, 2026.
What This Means
The stock is currently experiencing a period of consolidation and downward pressure, characterized by a five-day losing streak and a substantial reduction in trading volume. Technical indicators suggest a cooling phase, with the price oscillating near the 20-week moving average and momentum indicators like the RSI and MACD signaling a bearish trend.
While the company continues to engage with institutional investors and maintain regulatory compliance, the market sentiment remains cautious. The recent financial performance, marked by year-over-year declines in revenue and profit for the quarter ending March 2026, continues to influence investor evaluation of the company's growth potential.
Latest Quarter Info
For the Mar 2026 period, the company reported revenue of 7546.0. This figure indicates a decline in revenue momentum, with both quarter-over-quarter (QoQ) and year-over-year (YoY) percentages showing negative trends at -13.8% and -11.5% respectively. Profitability also faced significant headwinds, as evidenced by a sharp decrease in net profit. The net profit saw a substantial QoQ drop of -81.4% and a YoY decline of -86.1%. Operating margin remained stable at 5.0%, suggesting that core operational efficiency was maintained despite the revenue downturn. However, the mixed signals from revenue and profit trends, coupled with a negative tax percentage, warrant further examination of the underlying business dynamics.